Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial

Sarah H Nash; Jeannette M Schenk; Alan R Kristal; Phillis J Goodman; M Scott Lucia; Howard L Parnes; Ian M Thompson; Scott M Lippman; Xiaoling Song; Bora Gurel; Angelo De Marzo; Elizabeth A Platz

doi:10.1158/1940-6207.CAPR-14-0398

Back

Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial

Journal article

Open access

Peer reviewed

Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial

Sarah H Nash, Jeannette M Schenk, Alan R Kristal, Phillis J Goodman, M Scott Lucia, Howard L Parnes, Ian M Thompson, Scott M Lippman, Xiaoling Song, Bora Gurel, …

Cancer prevention research (Philadelphia, Pa.), Vol.8(7), pp.590-596

07/2015

DOI: 10.1158/1940-6207.CAPR-14-0398

PMCID: PMC4491033

PMID: 25926387

Files and links (1)

url

https://doi.org/10.1158/1940-6207.CAPR-14-0398View

Published (Version of record) Open Access

Abstract

Inflammation may play an etiologic role in prostate cancer. Several dietary factors influence inflammation; studies have shown that long-chain n-3 polyunsaturated fatty acids are anti-inflammatory, whereas n-6 and trans fatty acids are proinflammatory. We evaluated whether serum phospholipid n-3, n-6, and trans fatty acids were associated with intraprostatic inflammation, separately in 191 prostate cancer cases and 247 controls from the placebo arm of the Prostate Cancer Prevention Trial (PCPT). Men without a prostate cancer diagnosis underwent prostate biopsy at trial end, and benign prostate tissue inflammation was evaluated in approximately three biopsy cores per man; this was expressed as no, some, or all cores with inflammation. In controls, serum eicosapentaenoic acid [OR of all cores with inflammation versus none (95% CI), 0.35 (0.14-0.89)] and docosahexaenoic acid [OR (95% CI), 0.42 (0.17-1.02)] were inversely associated with, whereas linoleic acid [OR (95% CI), 3.85 (1.41-10.55)] was positively associated with intraprostatic inflammation. Serum trans fatty acids were not associated with intraprostatic inflammation. No significant associations were observed in cases; however, we could not rule out a positive association with linoleic acid and an inverse association with arachidonic acid. Thus, in the PCPT, we found that serum n-3 fatty acids were inversely, n-6 fatty acids were positively, and trans fatty acids were not associated with intraprostatic inflammation in controls. Although, in theory, inflammation could mediate associations of serum fatty acids with prostate cancer risk, our findings cannot explain the epidemiologic associations observed with n-3 and n-6 fatty acids.

Aged

Chromatography, Thin Layer

Fatty Acids, Omega-3 - blood

Fatty Acids, Omega-6 - blood

Humans

Inflammation - blood

Inflammation - epidemiology

Male

Middle Aged

Phospholipids

Prevalence

Prostate - pathology

Prostatic Neoplasms - blood

Prostatic Neoplasms - prevention & control

Details

Title: Subtitle: Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial
Creators: Sarah H Nash - Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland
Jeannette M Schenk - Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington
Alan R Kristal - Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington
Phillis J Goodman - Southwest Oncology Group Statistical Center, Seattle, Washington
M Scott Lucia - Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Denver, Colorado
Howard L Parnes - Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland
Ian M Thompson - Department of Urology, School of Medicine, University of Texas Health Science Center, San Antonio, Texas
Scott M Lippman - Office of the Director, Moores Cancer Center, University of California at San Diego, San Diego, California
Xiaoling Song - Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington
Bora Gurel - Department of Pathology, Kocaeli University School of Medicine, Kocaeli, Turkey
Angelo De Marzo - Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland. James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Elizabeth A Platz - Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland. James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. eplatz1@jhu.edu
Resource Type: Journal article
Publication Details: Cancer prevention research (Philadelphia, Pa.), Vol.8(7), pp.590-596
DOI: 10.1158/1940-6207.CAPR-14-0398
PMID: 25926387
PMCID: PMC4491033
NLM abbreviation: Cancer Prev Res (Phila)
ISSN: 1940-6207
eISSN: 1940-6215
Grant note: U10 CA037429 / NCI NIH HHS P30 CA006973 / NCI NIH HHS U10CA37429 / NCI NIH HHS UG1 CA189974 / NCI NIH HHS P50 CA58236 / NCI NIH HHS P50 CA058236 / NCI NIH HHS UM1 CA182883 / NCI NIH HHS U10 CA180834 / NCI NIH HHS P01 CA108964 / NCI NIH HHS 5UM1CA182883-01 / NCI NIH HHS
Language: English
Date published: 07/2015
Academic Unit: Epidemiology; Center for Social Science Innovation
Record Identifier: 9984214808702771

Metrics

24 Record Views

9 Times Cited - Web of Science